{"transactions":[{"id":722627,"issuer":{"id":2452,"kind":"organization","name":"Septerna, Inc.","symbol":"SEPN"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-30T23:00:12.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option vest in full upon the earlier of (i) June 26, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":37.34,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-26-291055","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000119312526291055/ownership.xml","form_type":"4"}},{"id":737540,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-15T21:49:39.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":18980,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy."}],"balance_after":38116,"source":{"system":"sec-edgar","filing":"0001377202-26-000007","document":"wk-form4_1781560173.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000137720226000007/wk-form4_1781560173.xml","form_type":"4"}},{"id":737539,"issuer":{"id":4115,"kind":"organization","name":"Organon & Co."},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock","published_at":"2026-06-15T20:41:46.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":17857.143,"price":13.44,"value":240000.00192,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each phantom stock unit is an economic equivalent of one share of Organon & Co. (\"Organon\") common stock, or 1-for-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the \"Plan\") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the \"Plan\") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026."}],"balance_after":81495.885,"derivative":{"underlying":"Common Stock","underlying_shares":17857.143},"source":{"system":"sec-edgar","filing":"0001628280-26-043256","document":"wk-form4_1781556099.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000162828026043256/wk-form4_1781556099.xml","form_type":"4"}},{"id":759321,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restriced Stock Unit","published_at":"2026-05-29T22:03:31.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":2567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":2567,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2567},"source":{"system":"sec-edgar","filing":"0001377202-26-000006","document":"wk-form4_1780092209.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000137720226000006/wk-form4_1780092209.xml","form_type":"4"}},{"id":768859,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-05-21T23:24:25.000Z","date":"2026-05-21","kind":"exercise","planned":false,"acquired":false,"shares":1659,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1659},"source":{"system":"sec-edgar","filing":"0001377202-26-000004","document":"wk-form4_1779405862.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000137720226000004/wk-form4_1779405862.xml","form_type":"4"}},{"id":768858,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T23:24:25.000Z","date":"2026-05-21","kind":"exercise","planned":false,"acquired":true,"shares":1659,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4088,"source":{"system":"sec-edgar","filing":"0001377202-26-000004","document":"wk-form4_1779405862.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000137720226000004/wk-form4_1779405862.xml","form_type":"4"}},{"id":1104737,"issuer":{"id":2452,"kind":"organization","name":"Septerna, Inc.","symbol":"SEPN"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T22:44:30.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":16623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in full upon the earlier of (i) June 17, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":16623,"derivative":{"exercise_price":10.24,"expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":16623},"source":{"system":"sec-edgar","filing":"0000950170-25-088622","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000095017025088622/ownership.xml","form_type":"4"}},{"id":1109510,"issuer":{"id":4115,"kind":"organization","name":"Organon & Co."},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock","published_at":"2025-06-16T21:34:12.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":23904.382,"price":10.04,"value":239999.99528,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each phantom stock unit is an economic equivalent of one share of Organon & Co. (\"Organon\") common stock, or 1-for-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the \"Plan\") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the \"Plan\") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Holdings include phantom stock units acquired in dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025 and June 12, 2025."}],"balance_after":63054.148,"derivative":{"underlying":"Common Stock","underlying_shares":23904.382},"source":{"system":"sec-edgar","filing":"0001821825-25-000055","document":"wk-form4_1750109646.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000182182525000055/wk-form4_1750109646.xml","form_type":"4"}},{"id":1136774,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-05-22T23:47:00.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":22750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended."}],"balance_after":22750,"derivative":{"exercise_price":18.19,"expiration_date":"2035-05-20","underlying":"Ordinary Shares","underlying_shares":22750},"source":{"system":"sec-edgar","filing":"0001651308-25-000090","document":"wk-form4_1747957614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000165130825000090/wk-form4_1747957614.xml","form_type":"4"}},{"id":1136773,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-05-22T23:47:00.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":10985,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended."}],"balance_after":19136,"source":{"system":"sec-edgar","filing":"0001651308-25-000090","document":"wk-form4_1747957614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000165130825000090/wk-form4_1747957614.xml","form_type":"4"}},{"id":1138147,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-05-22T21:28:01.000Z","date":"2025-05-22","kind":"exercise","planned":false,"acquired":false,"shares":1435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU award was granted to the Reporting Person on May 22, 2024 and is fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU award was granted to the Reporting Person on May 22, 2024 and is fully vested."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1435},"source":{"system":"sec-edgar","filing":"0000914475-25-000131","document":"wk-form4_1747949275.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000131/wk-form4_1747949275.xml","form_type":"4"}},{"id":1138146,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2025-05-22T21:28:01.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":3305,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests in 12 monthly installments beginning June 21, 2025."}],"balance_after":3305,"derivative":{"exercise_price":120.56,"expiration_date":"2035-05-21","underlying":"Common Stock","underlying_shares":3305},"source":{"system":"sec-edgar","filing":"0000914475-25-000131","document":"wk-form4_1747949275.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000131/wk-form4_1747949275.xml","form_type":"4"}},{"id":1138145,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-05-22T21:28:01.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":1659,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest in full on May 21, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest in full on May 21, 2026."}],"balance_after":1659,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1659},"source":{"system":"sec-edgar","filing":"0000914475-25-000131","document":"wk-form4_1747949275.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000131/wk-form4_1747949275.xml","form_type":"4"}},{"id":1138144,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-22T21:28:01.000Z","date":"2025-05-22","kind":"exercise","planned":false,"acquired":true,"shares":1435,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2429,"source":{"system":"sec-edgar","filing":"0000914475-25-000131","document":"wk-form4_1747949275.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000131/wk-form4_1747949275.xml","form_type":"4"}},{"id":1393852,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2024-10-02T23:21:19.000Z","date":"2024-09-30","kind":"grant","planned":false,"acquired":true,"shares":17238,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended."}],"balance_after":17238,"derivative":{"exercise_price":17.27,"expiration_date":"2034-09-29","underlying":"Ordinary Shares","underlying_shares":17238},"source":{"system":"sec-edgar","filing":"0001651308-24-000131","document":"wk-form4_1727911273.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000165130824000131/wk-form4_1727911273.xml","form_type":"4"}},{"id":1393851,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-10-02T23:21:19.000Z","date":"2024-09-30","kind":"grant","planned":false,"acquired":true,"shares":8151,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended."}],"balance_after":8151,"source":{"system":"sec-edgar","filing":"0001651308-24-000131","document":"wk-form4_1727911273.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000165130824000131/wk-form4_1727911273.xml","form_type":"4"}},{"id":1483119,"issuer":{"id":4115,"kind":"organization","name":"Organon & Co."},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock","published_at":"2024-06-11T19:17:53.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":9638.554,"price":20.75,"value":199999.9955,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each phantom stock unit is an economic equivalent of one share of Organon & Co. (\"Organon\") common stock, or 1-for-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the \"Plan\") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the \"Plan\") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Holdings include phantom stock acquired in dividend reinvestment transactions on June 15, 2023, September 14, 2023, December 14, 2023 and March 14, 2024."}],"balance_after":36783.9,"derivative":{"underlying":"Common Stock","underlying_shares":9638.554},"source":{"system":"sec-edgar","filing":"0001821825-24-000079","document":"wk-form4_1718133465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000182182524000079/wk-form4_1718133465.xml","form_type":"4"}},{"id":1504414,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2024-05-23T22:34:03.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":2982,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests in 12 monthly installments beginning June 22, 2024."}],"balance_after":2982,"derivative":{"exercise_price":139.43,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":2982},"source":{"system":"sec-edgar","filing":"0000914475-24-000154","document":"wk-form4_1716503634.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000154/wk-form4_1716503634.xml","form_type":"4"}},{"id":1504413,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-05-23T22:34:03.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":1435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest in full on May 22, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest in full on May 22, 2025."}],"balance_after":1435,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1435},"source":{"system":"sec-edgar","filing":"0000914475-24-000154","document":"wk-form4_1716503634.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000154/wk-form4_1716503634.xml","form_type":"4"}},{"id":1507794,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-05-21T21:35:30.000Z","date":"2024-05-17","kind":"exercise","planned":true,"acquired":false,"shares":2100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU award was granted to the Reporting Person on May 17, 2023 and is fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU award was granted to the Reporting Person on May 17, 2023 and is fully vested."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2100},"source":{"system":"sec-edgar","filing":"0000914475-24-000138","document":"wk-form4_1716327316.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000138/wk-form4_1716327316.xml","form_type":"4"}},{"id":1507793,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-21T21:35:30.000Z","date":"2024-05-17","kind":"sale","planned":true,"acquired":false,"shares":1106,"price":141.9018,"value":156943.3908,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.81 to $142.33. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range"}],"balance_after":994,"source":{"system":"sec-edgar","filing":"0000914475-24-000138","document":"wk-form4_1716327316.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000138/wk-form4_1716327316.xml","form_type":"4"}},{"id":1507792,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-21T21:35:30.000Z","date":"2024-05-17","kind":"exercise","planned":true,"acquired":true,"shares":2100,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2100,"source":{"system":"sec-edgar","filing":"0000914475-24-000138","document":"wk-form4_1716327316.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000138/wk-form4_1716327316.xml","form_type":"4"}},{"id":1672765,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true}}],"security":"Option to Purchase Common Stock","published_at":"2024-01-24T01:38:09.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7520,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":45.66,"expiration_date":"2033-01-20","underlying":"Common Stock","underlying_shares":7520},"source":{"system":"sec-edgar","filing":"0001140361-24-003537","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000114036124003537/form4.xml","form_type":"4"}},{"id":1672764,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-01-24T01:38:09.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6808,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the \"Converted Cash Award\"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-003537","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000114036124003537/form4.xml","form_type":"4"}},{"id":1672763,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-01-24T01:38:09.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5252,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units (\"RSUs\") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU."}],"balance_after":6808,"source":{"system":"sec-edgar","filing":"0001140361-24-003537","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000114036124003537/form4.xml","form_type":"4"}},{"id":1672762,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-01-24T01:38:09.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4162,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company (\"BMS\"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of January 23, 2024 (such date and time of such Merger, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Issuer (\"Company Common Stock\") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the \"Closing Consideration\") and (B) one contingent value right (a \"CVR\"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the \"Merger Consideration\"), without interest and subject to any withholding taxes."}],"balance_after":12060,"source":{"system":"sec-edgar","filing":"0001140361-24-003537","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000114036124003537/form4.xml","form_type":"4"}},{"id":1691298,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-03T23:24:30.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":6808,"price":58.75,"value":399970.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date."}],"balance_after":16222,"source":{"system":"sec-edgar","filing":"0001628280-24-000302","document":"wk-form4_1704324252.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000162828024000302/wk-form4_1704324252.xml","form_type":"4"}},{"id":1856960,"issuer":{"id":4115,"kind":"organization","name":"Organon & Co."},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock","published_at":"2023-06-13T21:00:21.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":10086,"price":19.83,"value":200005.38,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each phantom stock unit is an economic equivalent of one share of Organon & Co. (\"Organon\") common stock, or 1-for-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the \"Plan\") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the \"Plan\") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Holdings include phantom stock acquired in dividend reinvestment transactions on June 16, 2022, September 15, 2022, December 15, 2022 and March 16, 2023."}],"balance_after":25594,"derivative":{"underlying":"Common Stock","underlying_shares":10086},"source":{"system":"sec-edgar","filing":"0001209191-23-036798","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919123036798/doc4.xml","form_type":"4"}},{"id":1885696,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-05-19T21:22:50.000Z","date":"2023-05-17","kind":"grant","planned":false,"acquired":true,"shares":2100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units will vest in full on May 17, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units will vest in full on May 17, 2024."}],"balance_after":2100,"derivative":{"underlying":"Common Stock","underlying_shares":2100},"source":{"system":"sec-edgar","filing":"0001209191-23-031127","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123031127/doc4.xml","form_type":"4"}},{"id":1885695,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2023-05-19T21:22:50.000Z","date":"2023-05-17","kind":"grant","planned":false,"acquired":true,"shares":4290,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests in 12 monthly installments beginning June 17, 2023."}],"balance_after":4290,"derivative":{"exercise_price":95.27,"expiration_date":"2033-05-17","underlying":"Common Stock","underlying_shares":4290},"source":{"system":"sec-edgar","filing":"0001209191-23-031127","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123031127/doc4.xml","form_type":"4"}},{"id":2047298,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non Qualified Stock Option (right to buy)","published_at":"2023-01-24T21:03:15.000Z","date":"2023-01-20","kind":"grant","acquired":true,"shares":7520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":7520,"derivative":{"exercise_price":45.66,"expiration_date":"2033-01-20","underlying":"Common Stock","underlying_shares":7520},"source":{"system":"sec-edgar","filing":"0001214659-23-001038","document":"marketforms-58261.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000121465923001038/marketforms-58261.xml","form_type":"4"}},{"id":2047297,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-24T21:03:15.000Z","date":"2023-01-20","kind":"grant","acquired":true,"shares":4444,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs).  Shares will vest 100% on the anniversary of the grant date."}],"balance_after":9414,"source":{"system":"sec-edgar","filing":"0001214659-23-001038","document":"marketforms-58261.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000121465923001038/marketforms-58261.xml","form_type":"4"}},{"id":2232339,"issuer":{"id":4115,"kind":"organization","name":"Organon & Co."},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock","published_at":"2022-06-14T23:42:21.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":5640,"price":35.46,"value":199994.4,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each phantom stock unit is an economic equivalent of one share of Organon & Co. (\"Organon\") common stock, or 1-for-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the \"Plan\") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the \"Plan\") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Holdings include phantom stock acquired in dividend reinvestment transactions on September 13, 2021, December 16, 2021 and March 17, 2022."}],"balance_after":14935,"derivative":{"underlying":"Common Stock","underlying_shares":5640},"source":{"system":"sec-edgar","filing":"0001104659-22-071143","document":"tm2218336-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000110465922071143/tm2218336-11_4seq1.xml","form_type":"4"}},{"id":2238805,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-08T23:10:03.000Z","date":"2022-06-06","kind":"grant","acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 8.33% of the total shares monthly, commencing July 6, 2022, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2023 annual stockholders meeting or June 6, 2023,  subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":18500,"derivative":{"exercise_price":4.44,"expiration_date":"2032-06-05","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-22-035212","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919122035212/doc4.xml","form_type":"4"}},{"id":2262529,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2022-05-20T20:16:10.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":9724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests in 12 monthly installments beginning June 18, 2022."}],"balance_after":9724,"derivative":{"exercise_price":84.95,"expiration_date":"2032-05-18","underlying":"Common Stock","underlying_shares":9724},"source":{"system":"sec-edgar","filing":"0001209191-22-030998","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122030998/doc4.xml","form_type":"4"}},{"id":2433466,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non Qualified Stock Option (right to buy)","published_at":"2022-01-18T23:17:13.000Z","date":"2022-01-14","kind":"grant","acquired":true,"shares":3688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":3688,"derivative":{"exercise_price":124.31,"expiration_date":"2032-01-13","underlying":"Common Stock","underlying_shares":3688},"source":{"system":"sec-edgar","filing":"0001214659-22-000841","document":"marketforms-55084.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000121465922000841/marketforms-55084.xml","form_type":"4"}},{"id":2433465,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-18T23:17:13.000Z","date":"2022-01-14","kind":"grant","acquired":true,"shares":2546,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs).  Shares will vest 100% on the anniversary of the grant date."}],"balance_after":4970,"source":{"system":"sec-edgar","filing":"0001214659-22-000841","document":"marketforms-55084.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000121465922000841/marketforms-55084.xml","form_type":"4"}},{"id":2677138,"issuer":{"id":4115,"kind":"organization","name":"Organon & Co."},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock","published_at":"2021-06-09T00:31:44.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":9061,"price":36.05,"value":326649.05,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"1-for-1"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the Separation, which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,512 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the Separation, which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,512 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases."}],"balance_after":9061,"derivative":{"underlying":"Common Stock","underlying_shares":9061},"source":{"system":"sec-edgar","filing":"0000899243-21-022669","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000089924321022669/doc4.xml","form_type":"4"}},{"id":2678900,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-07T21:07:47.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 8.33% of the total shares monthly, commencing July 3, 2021, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2022 annual stockholders meeting or June 3, 2022,  subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":18500,"derivative":{"exercise_price":18.21,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-21-038699","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919121038699/doc4.xml","form_type":"4"}},{"id":2703969,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2021-05-20T20:12:43.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":8833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests in 12 equal monthly installments beginning June 19, 2021."}],"balance_after":8833,"derivative":{"exercise_price":92.35,"exercise_date":"2021-06-19","expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":8833},"source":{"system":"sec-edgar","filing":"0001209191-21-034395","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121034395/doc4.xml","form_type":"4"}},{"id":2715979,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-12T20:09:29.000Z","date":"2021-05-10","kind":"grant","acquired":true,"shares":32800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of May 10, 2022 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after May 10, 2021, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":32800,"derivative":{"exercise_price":8.07,"expiration_date":"2031-05-09","underlying":"Common Stock","underlying_shares":32800},"source":{"system":"sec-edgar","filing":"0001209191-21-032025","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919121032025/doc4.xml","form_type":"4"}},{"id":2767701,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non Qualified Stock Option (right to buy)","published_at":"2021-03-30T21:41:56.000Z","date":"2021-03-26","kind":"grant","acquired":true,"shares":3523,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the Option vest and become exercisable in 36 equal monthly installments following the date of grant."}],"balance_after":3523,"derivative":{"exercise_price":164.98,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":3523},"source":{"system":"sec-edgar","filing":"0001214659-21-003636","document":"marketforms-52136.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000121465921003636/marketforms-52136.xml","form_type":"4"}},{"id":2767700,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-30T21:41:56.000Z","date":"2021-03-26","kind":"grant","acquired":true,"shares":2424,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs).  Shares will vest 1/3rd annually on the anniversary of the grant date."}],"balance_after":2424,"source":{"system":"sec-edgar","filing":"0001214659-21-003636","document":"marketforms-52136.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000121465921003636/marketforms-52136.xml","form_type":"4"}},{"id":2829988,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Common Stock","published_at":"2021-02-27T00:02:07.000Z","date":"2021-02-10","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. (\"Panacea\"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea (\"Merger Sub\"), and Nuvation Bio Inc. (\"Legacy Nuvation\") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the \"Business Combination\"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. (\"Panacea\"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea (\"Merger Sub\"), and Nuvation Bio Inc. (\"Legacy Nuvation\") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the \"Business Combination\"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. (\"Panacea\"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea (\"Merger Sub\"), and Nuvation Bio Inc. (\"Legacy Nuvation\") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the \"Business Combination\"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001213900-21-012235","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000121390021012235/ownership.xml","form_type":"4"}},{"id":2829987,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-02-27T00:02:07.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":10000,"price":10,"value":100000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Acquired pursuant to one of a number of subscription agreements that Panacea entered into with various investors pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination, an aggregate of 47,655,000 shares of Class A Common Stock at a price of $10.00 per share."}],"balance_after":35000,"source":{"system":"sec-edgar","filing":"0001213900-21-012235","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000121390021012235/ownership.xml","form_type":"4"}},{"id":2829986,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-02-27T00:02:07.000Z","date":"2021-02-10","kind":"exercise","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. (\"Panacea\"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea (\"Merger Sub\"), and Nuvation Bio Inc. (\"Legacy Nuvation\") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the \"Business Combination\"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001213900-21-012235","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000121390021012235/ownership.xml","form_type":"4"}},{"id":3004920,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Finance"}}],"security":"Common Stock","published_at":"2020-10-16T23:15:35.000Z","date":"2020-10-14","kind":"sale","acquired":false,"shares":375,"price":87.99,"value":32996.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":97812,"source":{"system":"sec-edgar","filing":"0001209191-20-055172","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120055172/doc4.xml","form_type":"4"}},{"id":3051996,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-19T18:11:36.000Z","date":"2020-08-17","kind":"exercise","acquired":false,"shares":3669,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/4th of the option vested one year from March 1, 2018 and then 1/48th of the option vested monthly thereafter."}],"balance_after":15312,"derivative":{"exercise_price":48.43,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":3669},"source":{"system":"sec-edgar","filing":"0001209191-20-047455","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120047455/doc4.xml","form_type":"4"}},{"id":3051995,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-19T18:11:36.000Z","date":"2020-08-17","kind":"exercise","acquired":false,"shares":7188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/4th of the option vested one year from March 1, 2019 and then 1/48th of the option vested monthly thereafter."}],"balance_after":15812,"derivative":{"exercise_price":67.55,"expiration_date":"2029-03-01","underlying":"Common Stock","underlying_shares":7188},"source":{"system":"sec-edgar","filing":"0001209191-20-047455","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120047455/doc4.xml","form_type":"4"}},{"id":3051994,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-19T18:11:36.000Z","date":"2020-08-17","kind":"exercise","acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/4th of the option vested one year from June 1, 2016 and then 1/48th of the option vested monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":70.57,"expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001209191-20-047455","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120047455/doc4.xml","form_type":"4"}},{"id":3051993,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-08-19T18:11:36.000Z","date":"2020-08-17","kind":"sale","acquired":false,"shares":3669,"price":88.38,"value":324266.22,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.17 to $88.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":98187,"source":{"system":"sec-edgar","filing":"0001209191-20-047455","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120047455/doc4.xml","form_type":"4"}},{"id":3051992,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-08-19T18:11:36.000Z","date":"2020-08-17","kind":"exercise","acquired":true,"shares":3669,"price":48.43,"value":177689.67,"ownership":{"direct":true},"balance_after":101856,"source":{"system":"sec-edgar","filing":"0001209191-20-047455","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120047455/doc4.xml","form_type":"4"}},{"id":3051991,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-08-19T18:11:36.000Z","date":"2020-08-17","kind":"sale","acquired":false,"shares":7188,"price":88.38,"value":635275.44,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.17 to $88.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":98187,"source":{"system":"sec-edgar","filing":"0001209191-20-047455","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120047455/doc4.xml","form_type":"4"}},{"id":3051990,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-08-19T18:11:36.000Z","date":"2020-08-17","kind":"exercise","acquired":true,"shares":7188,"price":67.55,"value":485549.4,"ownership":{"direct":true},"balance_after":105375,"source":{"system":"sec-edgar","filing":"0001209191-20-047455","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120047455/doc4.xml","form_type":"4"}},{"id":3051989,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-08-19T18:11:36.000Z","date":"2020-08-17","kind":"sale","acquired":false,"shares":500,"price":88.38,"value":44190.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.17 to $88.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":98187,"source":{"system":"sec-edgar","filing":"0001209191-20-047455","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120047455/doc4.xml","form_type":"4"}},{"id":3051988,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-08-19T18:11:36.000Z","date":"2020-08-17","kind":"exercise","acquired":true,"shares":500,"price":70.57,"value":35285.0,"ownership":{"direct":true},"balance_after":98687,"source":{"system":"sec-edgar","filing":"0001209191-20-047455","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120047455/doc4.xml","form_type":"4"}},{"id":3051987,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-08-19T18:11:36.000Z","date":"2020-08-17","kind":"sale","acquired":false,"shares":2560,"price":88.54,"value":226662.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.45 to $88.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":98187,"source":{"system":"sec-edgar","filing":"0001209191-20-047455","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120047455/doc4.xml","form_type":"4"}},{"id":3051986,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-08-19T18:11:36.000Z","date":"2020-08-17","kind":"sale","acquired":false,"shares":461,"price":88.24,"value":40678.64,"ownership":{"direct":true},"balance_after":100747,"source":{"system":"sec-edgar","filing":"0001209191-20-047455","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120047455/doc4.xml","form_type":"4"}},{"id":3118241,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-08T21:36:42.000Z","date":"2020-06-05","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is fully vested on June 5, 2021, subject to the reporting person's provision of service to the issuer on the vesting date."}],"balance_after":12000,"derivative":{"exercise_price":9.83,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-20-035037","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120035037/doc4.xml","form_type":"4"}},{"id":3119950,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-05T20:59:32.000Z","date":"2020-06-04","kind":"exercise","acquired":false,"shares":2564,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/4th of the option vested one year from March 1, 2018 and then 1/48th of the option vested monthly thereafter."}],"balance_after":18981,"derivative":{"exercise_price":48.43,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":2564},"source":{"system":"sec-edgar","filing":"0001209191-20-034710","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120034710/doc4.xml","form_type":"4"}},{"id":3119949,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-05T20:59:32.000Z","date":"2020-06-03","kind":"exercise","acquired":false,"shares":10234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/4th of the option vested one year from March 1, 2018 and then 1/48th of the option vested monthly thereafter."}],"balance_after":21545,"derivative":{"exercise_price":48.43,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":10234},"source":{"system":"sec-edgar","filing":"0001209191-20-034710","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120034710/doc4.xml","form_type":"4"}},{"id":3119948,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-06-05T20:59:32.000Z","date":"2020-06-04","kind":"sale","acquired":false,"shares":2564,"price":74.01,"value":189761.64,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.00 to $74.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":101208,"source":{"system":"sec-edgar","filing":"0001209191-20-034710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120034710/doc4.xml","form_type":"4"}},{"id":3119947,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-06-05T20:59:32.000Z","date":"2020-06-04","kind":"exercise","acquired":true,"shares":2564,"price":48.43,"value":124174.52,"ownership":{"direct":true},"balance_after":103772,"source":{"system":"sec-edgar","filing":"0001209191-20-034710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120034710/doc4.xml","form_type":"4"}},{"id":3119946,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-06-05T20:59:32.000Z","date":"2020-06-03","kind":"sale","acquired":false,"shares":10234,"price":74.23,"value":759669.82,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.01 to $74.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":101208,"source":{"system":"sec-edgar","filing":"0001209191-20-034710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120034710/doc4.xml","form_type":"4"}},{"id":3119945,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-06-05T20:59:32.000Z","date":"2020-06-03","kind":"exercise","acquired":true,"shares":10234,"price":48.43,"value":495632.62,"ownership":{"direct":true},"balance_after":111442,"source":{"system":"sec-edgar","filing":"0001209191-20-034710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120034710/doc4.xml","form_type":"4"}},{"id":3123328,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-06-03T18:19:33.000Z","date":"2020-06-01","kind":"tax_withholding","acquired":false,"shares":348,"price":69.38,"value":24144.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":101208,"source":{"system":"sec-edgar","filing":"0001209191-20-033885","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120033885/doc4.xml","form_type":"4"}},{"id":3140530,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-20T23:49:39.000Z","date":"2020-05-19","kind":"exercise","acquired":false,"shares":3907,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/4th of the option vested one year from June 1, 2016 and then 1/48th of the option vested and will vest monthly thereafter."}],"balance_after":500,"derivative":{"exercise_price":70.57,"expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":3907},"source":{"system":"sec-edgar","filing":"0001209191-20-031054","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120031054/doc4.xml","form_type":"4"}},{"id":3140529,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-20T23:49:39.000Z","date":"2020-05-19","kind":"exercise","acquired":false,"shares":3221,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/4th of the option vested one year from March 1, 2018 and then 1/48th of the option vested and will continue to vest monthly thereafter."}],"balance_after":31779,"derivative":{"exercise_price":48.43,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":3221},"source":{"system":"sec-edgar","filing":"0001209191-20-031054","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120031054/doc4.xml","form_type":"4"}},{"id":3140528,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-20T23:49:39.000Z","date":"2020-05-18","kind":"exercise","acquired":false,"shares":19593,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/4th of the option vested one year from June 1, 2016 and then 1/48th of the option vested and will vest monthly thereafter."}],"balance_after":4407,"derivative":{"exercise_price":70.57,"expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":19593},"source":{"system":"sec-edgar","filing":"0001209191-20-031054","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120031054/doc4.xml","form_type":"4"}},{"id":3140527,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-05-20T23:49:39.000Z","date":"2020-05-19","kind":"sale","acquired":false,"shares":3907,"price":73.32,"value":286461.24,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.05 to $73.66 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 612 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2020."}],"balance_after":101556,"source":{"system":"sec-edgar","filing":"0001209191-20-031054","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120031054/doc4.xml","form_type":"4"}},{"id":3140526,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-05-20T23:49:39.000Z","date":"2020-05-19","kind":"exercise","acquired":true,"shares":3907,"price":70.57,"value":275716.99,"ownership":{"direct":true},"balance_after":104851,"source":{"system":"sec-edgar","filing":"0001209191-20-031054","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120031054/doc4.xml","form_type":"4"}},{"id":3140525,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-05-20T23:49:39.000Z","date":"2020-05-19","kind":"sale","acquired":false,"shares":3221,"price":73.32,"value":236163.72,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.05 to $73.66 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":100944,"source":{"system":"sec-edgar","filing":"0001209191-20-031054","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120031054/doc4.xml","form_type":"4"}},{"id":3140524,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-05-20T23:49:39.000Z","date":"2020-05-19","kind":"exercise","acquired":true,"shares":3221,"price":48.43,"value":155993.03,"ownership":{"direct":true},"balance_after":104165,"source":{"system":"sec-edgar","filing":"0001209191-20-031054","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120031054/doc4.xml","form_type":"4"}},{"id":3140523,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-05-20T23:49:39.000Z","date":"2020-05-18","kind":"sale","acquired":false,"shares":2392,"price":73.29,"value":175309.68,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.01 to $73.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":100944,"source":{"system":"sec-edgar","filing":"0001209191-20-031054","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120031054/doc4.xml","form_type":"4"}},{"id":3140522,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-05-20T23:49:39.000Z","date":"2020-05-18","kind":"sale","acquired":false,"shares":19593,"price":73.34,"value":1436950.62,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.04 to $73.58 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":103336,"source":{"system":"sec-edgar","filing":"0001209191-20-031054","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120031054/doc4.xml","form_type":"4"}},{"id":3140521,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-05-20T23:49:39.000Z","date":"2020-05-18","kind":"exercise","acquired":true,"shares":19593,"price":70.57,"value":1382678.01,"ownership":{"direct":true},"balance_after":122929,"source":{"system":"sec-edgar","filing":"0001209191-20-031054","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120031054/doc4.xml","form_type":"4"}},{"id":3146892,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-15T20:00:17.000Z","date":"2020-05-13","kind":"grant","acquired":true,"shares":41038,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of May 13, 2021 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after May 13, 2020."}],"balance_after":41038,"derivative":{"exercise_price":6.62,"expiration_date":"2030-05-12","underlying":"Common Stock","underlying_shares":41038},"source":{"system":"sec-edgar","filing":"0001209191-20-029690","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919120029690/doc4.xml","form_type":"4"}},{"id":3156051,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-05-08T23:55:01.000Z","date":"2020-05-06","kind":"tax_withholding","acquired":false,"shares":248,"price":66.26,"value":16432.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":103336,"source":{"system":"sec-edgar","filing":"0001209191-20-028106","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120028106/doc4.xml","form_type":"4"}},{"id":3172223,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-04-21T19:39:07.000Z","date":"2020-04-19","kind":"tax_withholding","acquired":false,"shares":248,"price":58.57,"value":14525.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":103584,"source":{"system":"sec-edgar","filing":"0001209191-20-025193","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120025193/doc4.xml","form_type":"4"}},{"id":3231175,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-03-04T00:46:46.000Z","date":"2020-03-01","kind":"tax_withholding","acquired":false,"shares":2325,"price":56.08,"value":130386.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":103832,"source":{"system":"sec-edgar","filing":"0001209191-20-015736","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120015736/doc4.xml","form_type":"4"}},{"id":3231174,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-03-04T00:46:46.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":5634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 1,859 shares of common stock and 3,775 restricted stock units (\"RSUs\") into which previously granted performance stock units were converted on March 1, 2020 upon certification of the performance metric. The RSUs will fully vest on March 1, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":106157,"source":{"system":"sec-edgar","filing":"0001209191-20-015736","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919120015736/doc4.xml","form_type":"4"}},{"id":3293086,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2020-02-04T21:34:50.000Z","date":"2020-02-01","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option granted February 1, 2020 and vests in 36 equal monthly installments."}],"balance_after":15000,"derivative":{"exercise_price":100.08,"expiration_date":"2030-02-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-006379","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120006379/doc4.xml","form_type":"4"}},{"id":3392747,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2019-10-16T23:25:47.000Z","date":"2019-10-14","kind":"grant","acquired":true,"shares":1434,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on October 14, 2019 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":100523,"source":{"system":"sec-edgar","filing":"0001209191-19-053322","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919119053322/doc4.xml","form_type":"4"}},{"id":3411879,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-09-17T23:25:25.000Z","date":"2019-09-16","kind":"exercise","acquired":false,"shares":24880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4th of the option vested one year from November 1, 2013 and then 1/48th of the option vested monthly thereafter."}],"balance_after":2998,"derivative":{"exercise_price":6.86,"expiration_date":"2023-10-31","underlying":"Common Stock","underlying_shares":24880},"source":{"system":"sec-edgar","filing":"0001209191-19-049950","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919119049950/doc4.xml","form_type":"4"}},{"id":3411878,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-09-17T23:25:25.000Z","date":"2019-09-16","kind":"exercise","acquired":false,"shares":6963,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the option vested one year from May 21, 2012 and then 1/48th of the option vested monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":0.81,"expiration_date":"2022-08-01","underlying":"Common Stock","underlying_shares":6963},"source":{"system":"sec-edgar","filing":"0001209191-19-049950","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919119049950/doc4.xml","form_type":"4"}},{"id":3411877,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2019-09-17T23:25:25.000Z","date":"2019-09-16","kind":"exercise","acquired":true,"shares":24880,"price":6.86,"value":170676.8,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":99089,"source":{"system":"sec-edgar","filing":"0001209191-19-049950","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919119049950/doc4.xml","form_type":"4"}},{"id":3411876,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2019-09-17T23:25:25.000Z","date":"2019-09-16","kind":"exercise","acquired":true,"shares":6963,"price":0.81,"value":5640.03,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":74209,"source":{"system":"sec-edgar","filing":"0001209191-19-049950","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919119049950/doc4.xml","form_type":"4"}},{"id":3453507,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-30T20:05:39.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an \"In the Money Option\"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option provided for vesting in four equal annual installments beginning on October 25, 2019."}],"balance_after":0,"derivative":{"exercise_price":14.55,"expiration_date":"2028-10-25","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-19-043785","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043785/doc4.xml","form_type":"4"}},{"id":3453506,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-30T20:05:39.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an \"In the Money Option\"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option provided for vesting in four equal annual installments beginning on October 26, 2018."}],"balance_after":0,"derivative":{"exercise_price":10.47,"expiration_date":"2027-10-26","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-19-043785","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043785/doc4.xml","form_type":"4"}},{"id":3453505,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-30T20:05:39.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an \"In the Money Option\"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option provided for vesting in four equal annual installments beginning on April 27, 2018."}],"balance_after":0,"derivative":{"exercise_price":8.7,"expiration_date":"2027-04-27","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-19-043785","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043785/doc4.xml","form_type":"4"}},{"id":3453504,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-30T20:05:39.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 14, 2019, Array BioPharma Inc. (the \"Company\") entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Pfizer Inc. (\"Pfizer\") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer (\"Purchaser\"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares of Company common stock underlying each restricted stock unit (a \"Company RSU\") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-043785","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043785/doc4.xml","form_type":"4"}},{"id":3453503,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-30T20:05:39.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":5000,"price":48,"value":240000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 14, 2019, Array BioPharma Inc. (the \"Company\") entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Pfizer Inc. (\"Pfizer\") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer (\"Purchaser\"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-19-043785","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043785/doc4.xml","form_type":"4"}},{"id":3483801,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2019-06-19T21:55:15.000Z","date":"2019-06-17","kind":"grant","acquired":true,"shares":11610,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12th of the total shares monthly, beginning on July 7, 2019, with 100% of the total shares vested and exercisable on June 7, 2020, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":11610,"derivative":{"exercise_price":11.12,"expiration_date":"2029-06-16","underlying":"Common Stock","underlying_shares":11610},"source":{"system":"sec-edgar","filing":"0001209191-19-038103","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919119038103/doc4.xml","form_type":"4"}},{"id":3501802,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2019-06-04T22:49:22.000Z","date":"2019-06-01","kind":"tax_withholding","acquired":false,"shares":346,"price":54.93,"value":19005.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":67246,"source":{"system":"sec-edgar","filing":"0001209191-19-034540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919119034540/doc4.xml","form_type":"4"}},{"id":3514774,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2019-05-22T21:39:34.000Z","date":"2019-05-21","kind":"tax_withholding","acquired":false,"shares":381,"price":59.5,"value":22669.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":67592,"source":{"system":"sec-edgar","filing":"0001209191-19-032132","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919119032132/doc4.xml","form_type":"4"}},{"id":3536271,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2019-05-07T23:07:52.000Z","date":"2019-05-06","kind":"grant","acquired":true,"shares":1434,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on May 6, 2019 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 461 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2019."}],"balance_after":67973,"source":{"system":"sec-edgar","filing":"0001209191-19-028101","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919119028101/doc4.xml","form_type":"4"}},{"id":3550979,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2019-04-23T22:22:52.000Z","date":"2019-04-19","kind":"tax_withholding","acquired":false,"shares":248,"price":64.43,"value":15978.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":66078,"source":{"system":"sec-edgar","filing":"0001209191-19-025611","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919119025611/doc4.xml","form_type":"4"}},{"id":3553502,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-17T21:50:09.000Z","date":"2019-03-18","kind":"exercise","acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4th of the option vested one year from November 1, 2013 and then 1/48th of the option vested monthly thereafter."}],"balance_after":27878,"derivative":{"exercise_price":6.86,"expiration_date":"2023-10-31","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-19-025094","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919119025094/doc4a.xml","form_type":"4/A","original_submission_date":"2019-03-20"}},{"id":3553501,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2019-04-17T21:50:09.000Z","date":"2019-03-18","kind":"sale","acquired":false,"shares":14800,"price":70,"value":1036000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":66326,"source":{"system":"sec-edgar","filing":"0001209191-19-025094","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919119025094/doc4a.xml","form_type":"4/A","original_submission_date":"2019-03-20"}},{"id":3553500,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2019-04-17T21:50:09.000Z","date":"2019-03-18","kind":"exercise","acquired":true,"shares":12000,"price":6.86,"value":82320.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":81126,"source":{"system":"sec-edgar","filing":"0001209191-19-025094","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377202/000120919119025094/doc4a.xml","form_type":"4/A","original_submission_date":"2019-03-20"}}],"next_cursor":"2019-04-17T21:50:09.000000Z,3553500"}